Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

532 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostate.
Chen X, Augello MA, Liu D, Lin K, Hakansson A, Sjöström M, Khani F, Deonarine LD, Liu Y, Travascio-Green J, Wu J, Chan UI, Owiredu J, Loda M, Feng FY, Robinson BD, Davicioni E, Sboner A, Barbieri CE. Chen X, et al. Among authors: feng fy. Nat Commun. 2024 Dec 13;15(1):10675. doi: 10.1038/s41467-024-53734-z. Nat Commun. 2024. PMID: 39672812 Free PMC article.
Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer.
Markowski MC, Ren Y, Tierney M, Royce TJ, Yamashita R, Croucher D, Huang HC, Todorovic T, Chen E, Showalter TN, Carducci MA, Chen YH, Liu G, Parker CTA, Esteva A, Feng FY, Attard G, Sweeney CJ. Markowski MC, et al. Among authors: feng fy. Eur Urol Oncol. 2024 Dec 10:S2588-9311(24)00271-2. doi: 10.1016/j.euo.2024.11.009. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39665917
Androgen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer.
Chesner LN, Polesso F, Graff JN, Hawley JE, Smith AK, Lundberg A, Das R, Shenoy T, Sjöström M, Zhao F, Hu YM, Linder S, Chen WS, Hawkins RM, Shrestha R, Zhu X, Foye A, Li H, Kim LM, Bhalla M, O'loughlin T, Kuzuoglu-Ozturk D, Hua JT, Badura ML, Wilkinson S, Trostel SY, Bergman AM, Ruggero D, Drake CG, Sowalsky AG, Fong L, Cooperberg MR, Zwart W, Guan X, Ashworth A, Xia Z, Quigley DA, Gilbert LA, Feng FY, Moran AE. Chesner LN, et al. Among authors: feng fy. Cancer Discov. 2024 Dec 5. doi: 10.1158/2159-8290.CD-24-0559. Online ahead of print. Cancer Discov. 2024. PMID: 39652470
Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials.
Patel KR, Nguyen PL, Proudfoot JA, Liu Y, Pra AD, Spratt DE, Pollack A, Sandler HM, Efstathiou JA, Lawton C, Simko JP, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, Pugh SL, Davicioni E, Tran PT, Feng FY. Patel KR, et al. Among authors: feng fy. Eur Urol Oncol. 2024 Nov 13:S2588-9311(24)00246-3. doi: 10.1016/j.euo.2024.10.017. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39542826
Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer.
Wang JH, Deek MP, Mendes AA, Song Y, Shetty A, Bazyar S, Van der Eecken K, Chen E, Showalter TN, Royce TJ, Todorovic T, Huang HC, Houck SA, Yamashita R, Kiess AP, Song DY, Lotan T, DeWeese T, Marchionni L, Ren L, Sawant A, Simone N, Berlin A, Onal C, Esteva A, Feng FY, Tran PT, Sutera P, Ost P. Wang JH, et al. Among authors: feng fy. Radiother Oncol. 2025 Jan;202:110618. doi: 10.1016/j.radonc.2024.110618. Epub 2024 Nov 6. Radiother Oncol. 2025. PMID: 39510141 Free article.
Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology.
Tward JD, Huang HC, Esteva A, Mohamad O, van der Wal D, Simko JP, DeVries S, Zhang J, Joun S, Showalter TN, Schaeffer EM, Morgan TM, Monson JM, Wallace JA, Bahary JP, Sandler HM, Spratt DE, Rodgers JP, Feng FY, Tran PT. Tward JD, et al. Among authors: feng fy. JCO Precis Oncol. 2024 Oct;8:e2400145. doi: 10.1200/PO.24.00145. Epub 2024 Oct 24. JCO Precis Oncol. 2024. PMID: 39447096 Free PMC article. Clinical Trial.
Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis.
Karlsson P, Fyles A, Chang SL, Arrick B, Baehner FL, Malmström P, Fernö M, Holmberg E, Sjöström M, Liu FF, Cameron DA, Williams LJ, Bartlett JM, Dunlop J, Caldwell J, Loane JF, Mallon E, Piper T, Kunkler I, Feng FY, Speers CW, Pierce LJ, Bennett JP, Taylor KJ. Karlsson P, et al. Among authors: feng fy. J Natl Cancer Inst. 2024 Oct 18:djae262. doi: 10.1093/jnci/djae262. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 39423142
532 results